Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 05 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Oxantel pamoate–albendazole for infection with soil-transmitted helminths

Treatment with oxantel pamoate–albendazole resulted in higher cure and egg-reduction rates for T. trichiura infection than the rates with standard therapy, reports this week's issue of the New England Journal of Medicine.

News image

Infections with soil-transmitted helminths (Ascaris lumbricoides, hookworm, and Trichuris trichiura) are widespread and often occur concomitantly.

These parasitic-worm infections are typically treated with albendazole or mebendazole, but both drugs show low efficacy against Trichuris trichiura.

Albendazole is the drug of choice against hookworm.

In this double-blind trial conducted on Pemba Island, Tanzania, Dr Benjamin Speich and colleagues randomly assigned children, 6 to 14 years of age, to receive one of 4 treatments.

The treatments included oxantel pamoate at a dose of 20 mg per kilogram of body weight, plus 400 mg of albendazole, administered on consecutive days, oxantel pamoate at a single dose of 20 mg per kilogram, albendazole at a single dose of 400 mg, or mebendazole at a single dose of 500 mg.

The researchers assessed the efficacy and safety profile of oxantel pamoate–albendazole when used in the treatment of Trichuris trichiura infection, and concomitant soil-transmitted helminth infection.

Adverse events were reported by 31% of all children
Alimentary Pharmacology & Therapeutics

Efficacy was determined by means of assessment of the cure rate and egg-reduction rate.

The team assessed adverse events were 4 times after treatment.

Complete data were available for 458 children, of whom 450 were infected with T. trichiura, 443 with hookworm, and 293 with A. lumbricoides.

The team observed that the cure rate of Trichuris trichiura infection was significantly higher with oxantel pamoate–albendazole than with mebendazole, as was the egg-reduction rate.

The cure rate and the egg-reduction rate was significantly lower than the rates with mebendazole.

Oxantel pamoate had low efficacy against hookworm and A. lumbricoides.

Adverse events were reported by 31% of all children.

Dr Speich's team concludes, "Treatment with oxantel pamoate–albendazole resulted in higher cure and egg-reduction rates for Trichuris trichiura infection than the rates with standard therapy."

N Engl J Med 2014; 370:610-620
14 February 2014

Go to top of page Email this page Email this page to a colleague

 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 05 December 2016 
Reducing hospitalization in IBD
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Treating Zenker's diverticulum
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 23 November 2016 
Quality assurance standards for colonoscopy
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 21 November 2016 
Financial incentives and colorectal cancer screening
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 17 November 2016 
Liver-related specialty care in patients with Hep C
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Physician perspectives on Hep C management
 15 November 2016 
Contraceptives and ulcerative colitis
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 
 11 November 2016 
Treatment of Hep C along with opioid agonist therapy
 11 November 2016 
Diabetes and liver cancer risk in Hep C cirrhosis
 11 November 2016 
Biomarker of cirrhosis progression
 10 November 2016 
Testosterone levels and cirrhosis outcomes in men
 10 November 2016 
Improving bowel quality before colonoscopy
 10 November 2016 
Fecal microbiota transplantation and CDI episodes
 09 November 2016 
Minimizing costs of esophagogastroduodenoscopy and colonoscopy
 09 November 2016 
Risk of TB in IBD patients receiving therapy
 09 November 2016 
Liver transplant wait-list and mortality in infants
 08 November 2016 
NSAIDS and risk of Barrett’s
 08 November 2016 
Ferritin levels and NAFLD mortality
 08 November 2016 
Alarms in the diagnosis of colorectal cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us